Mounjaro and Kidney Function: Is Tirzepatide Safe for Your Kidneys?

If you are taking Mounjaro (tirzepatide) for weight loss or type 2 diabetes, you may be wondering whether this medication is safe for your kidneys. Kidney function is an important consideration for anyone on long-term medication, and the growing body of clinical evidence on Mounjaro and kidney function is largely reassuring. In this guide, we explain what the research shows, who needs extra monitoring, and when to speak with your doctor.

As a doctor-led weight-loss service, CutKilo ensures that every patient receives a thorough medical review before starting treatment. Kidney health is one of the factors we assess, and understanding how tirzepatide interacts with renal function helps us tailor treatment safely.

For most patients, Mounjaro does not harm the kidneys. In fact, pooled data from the SURPASS clinical trials show that tirzepatide reduces albuminuria (a key marker of kidney stress) by 19 to 26 per cent, depending on dose. A 2025 study published in the Journal of the American Society of Nephrology found that tirzepatide slowed the decline in estimated glomerular filtration rate (eGFR) in patients with prediabetes and preserved kidney function. However, patients with severe chronic kidney disease (CKD stage 4 or 5) should be monitored more closely, as limited data exist for this group.

Your kidneys filter waste products from the blood, regulate fluid balance, and help control blood pressure. Two key measurements tell your doctor how well they are performing: the estimated glomerular filtration rate (eGFR), which reflects overall filtering capacity, and the urine albumin-to-creatinine ratio (uACR), which detects early protein leakage that signals kidney stress.

Obesity and type 2 diabetes are two of the most common causes of chronic kidney disease in the UK. Excess weight increases intra-glomerular pressure, while sustained high blood glucose damages the tiny blood vessels inside the kidneys. By helping patients lose weight and improve glycaemic control, Mounjaro can address both of these underlying risk factors simultaneously.

The SURPASS programme is the largest clinical trial series for tirzepatide, spanning five randomised controlled studies involving thousands of participants with type 2 diabetes. A pooled post-hoc analysis published in Diabetes Care (2025) examined renal outcomes across SURPASS 1 through 5 and found consistent, dose-dependent reductions in albuminuria.

Specifically, the adjusted mean percentage change from baseline in uACR was a reduction of 19.3 per cent with tirzepatide 5 mg, 22.0 per cent with 10 mg, and 26.3 per cent with 15 mg at week 40 to 42. Approximately half of this improvement appeared to be related to weight loss, with the remainder likely driven by direct metabolic and anti-inflammatory effects of the medication.

Furthermore, data presented at the American Society of Nephrology Kidney Week in 2025 compared tirzepatide with dulaglutide in patients with high-risk CKD and type 2 diabetes. The risk of the composite kidney outcome (a measure combining kidney function decline and albuminuria worsening) was 33 per cent lower with tirzepatide: 16.7 per cent versus 23.0 per cent. These findings suggest that tirzepatide may offer kidney-protective benefits beyond simple glucose lowering.

High blood pressure is one of the leading causes of kidney damage, and sustained hypertension accelerates the decline in eGFR over time. Tirzepatide has been shown to reduce systolic blood pressure by 2.8 to 12.6 mmHg across the SURPASS programme, which contributes indirectly to kidney protection. If you are managing Mounjaro and blood pressure together, these dual benefits are an important part of your overall treatment picture.

Similarly, reductions in cholesterol, insulin resistance, and systemic inflammation observed with tirzepatide create a broader cardiovascular and metabolic environment that supports kidney health. The SUMMIT trial (2025) confirmed that tirzepatide reduces the risk of major adverse heart failure events in patients with preserved ejection fraction, and that chronic kidney disease did not diminish these benefits.

While the data are reassuring for the majority of patients, certain groups should receive closer renal monitoring during treatment. Your doctor should check your kidney function before starting Mounjaro and at regular intervals thereafter if any of the following apply to you.

Patients with existing chronic kidney disease (particularly CKD stage 3b or higher, where eGFR is below 45) should have their kidney function monitored every three to six months. Additionally, if you have type 2 diabetes with known diabetic nephropathy, your uACR should be checked alongside HbA1c at each review. Patients taking medications that also affect the kidneys, such as ACE inhibitors, ARBs, or NSAIDs, warrant careful monitoring because the gastrointestinal side effects of Mounjaro (nausea, vomiting, diarrhoea) can cause dehydration, which temporarily reduces kidney perfusion.

The MHRA Summary of Product Characteristics for Mounjaro notes that acute kidney injury has been reported in post-marketing surveillance, primarily in patients who experienced severe dehydration from persistent gastrointestinal symptoms. For this reason, staying well hydrated is essential, particularly during the first few weeks of treatment or after a dose increase.

The most common way Mounjaro can affect kidney function indirectly is through dehydration. Nausea, vomiting, and diarrhoea are well-documented side effects, especially at the start of treatment or when stepping up to a higher dose. If fluid losses are not replaced, the kidneys receive less blood flow, and waste products can accumulate temporarily.

To reduce this risk, aim for at least 1.5 to 2 litres of water daily, and increase your intake if you experience any gastrointestinal symptoms. Sipping fluids throughout the day is more effective than drinking large volumes at once. If you develop persistent vomiting or diarrhoea lasting more than 48 hours, contact your prescribing doctor promptly. In rare cases, intravenous fluids may be needed to prevent acute kidney injury.

Patients who are already on diuretics (“water tablets”) for blood pressure should be especially vigilant, as the combination of reduced oral intake and increased urinary losses can compound the risk of dehydration.

In general, tirzepatide does not require dose adjustment for patients with mild to moderate kidney impairment (CKD stages 1 to 3a, eGFR above 45). The medication is primarily broken down by proteolytic cleavage rather than renal excretion, which means the kidneys play a relatively minor role in clearing it from the body.

For patients with severe kidney impairment (eGFR below 30) or those on dialysis, the evidence is limited because the SURPASS and SURMOUNT trials largely excluded this population. Prescribing in this group requires specialist input from both an endocrinologist or weight-management physician and a nephrologist. At CutKilo, we would not initiate treatment in patients with an eGFR below 30 without prior nephrology review and a shared-care arrangement.

Beyond simple safety, there is growing interest in whether tirzepatide actively protects the kidneys. The JASN 2025 study showed that among participants with prediabetes and obesity who had preserved eGFR at baseline, tirzepatide slowed the rate of eGFR decline over 176 weeks compared with placebo. This suggests that the medication may preserve kidney function over the long term, not merely avoid harming it.

The mechanisms behind this potential nephroprotection are thought to include reductions in intra-glomerular pressure from weight loss, improvements in insulin sensitivity that reduce glomerular hyperfiltration, and anti-inflammatory effects mediated through both the GLP-1 and GIP receptor pathways. Specifically, tirzepatide’s dual agonism may modulate inflammatory cytokines and oxidative stress within the renal tubules.

However, it is important to note that a dedicated kidney outcomes trial for tirzepatide has not yet been completed. The evidence so far comes from secondary analyses and post-hoc pooled data. Until a purpose-designed renal trial reports, the nephroprotective claim remains promising but unconfirmed.

The current clinical evidence on Mounjaro and kidney function is encouraging. Tirzepatide does not appear to harm the kidneys in the vast majority of patients, and pooled trial data suggest it may actively reduce markers of kidney stress such as albuminuria. The main kidney-related risk comes from dehydration caused by gastrointestinal side effects, which is manageable with adequate fluid intake and appropriate medical oversight. Patients with pre-existing kidney disease should have their renal function monitored regularly, and those with severe impairment should only proceed under specialist guidance.

Does Mounjaro damage the kidneys? No. Clinical trial data from the SURPASS programme show that tirzepatide reduces albuminuria (a marker of kidney stress) rather than increasing it. The main kidney risk is indirect, through dehydration from nausea or vomiting, which is preventable with adequate hydration.

Should I have my kidney function tested before starting Mounjaro? Yes. A baseline eGFR and uACR are recommended before starting treatment, particularly if you have type 2 diabetes, hypertension, or a family history of kidney disease. Your prescribing doctor should include this in your initial blood panel.

Can I take Mounjaro if I have stage 3 kidney disease? In most cases, yes. Tirzepatide does not require dose adjustment for CKD stages 1 to 3a (eGFR above 45). For stage 3b (eGFR 30 to 44), your doctor may proceed with closer monitoring. For eGFR below 30, specialist nephrology input is recommended before starting.

How much water should I drink while on Mounjaro to protect my kidneys? Aim for at least 1.5 to 2 litres of water per day, and increase this if you experience nausea, vomiting, or diarrhoea. Consistent hydration throughout the day is more effective than large volumes at once.

Will Mounjaro interact with my blood pressure medication? Mounjaro does not directly interact with most blood pressure medications, including ACE inhibitors and ARBs. However, if you are on diuretics, the combination of reduced fluid intake (from nausea) and increased urinary output could raise the risk of dehydration and temporary kidney strain. Let your doctor know all the medications you take.